Median Technologies Gains FDA Clearance for Lung Cancer Screening AI, Appoints Industry Veteran to Lead U.S. Expansion
Event summary
- Median Technologies received FDA 510(k) clearance for its eyonis® LCS software as a medical device for lung cancer screening on February 9, 2026.
- Oran Muduroglu, with over three decades of experience in medical imaging, was appointed President of Median eyonis Inc. to lead U.S. commercialization.
- Median signed a non-exclusive distribution agreement with Tempus AI to enhance commercial availability of eyonis® LCS across the U.S.
- The CMS reimbursement framework provides a predictable payment pathway for providers, with Medicare paying approximately $601–$700 per exam in 2026.
The big picture
Median Technologies' FDA clearance for eyonis® LCS positions it to capitalize on the substantial adoption potential in the U.S. lung cancer screening market, which includes approximately 14.5 million eligible Americans. The appointment of Oran Muduroglu, with his extensive experience in scaling medical imaging platforms, underscores the company's strategic focus on disciplined execution and rapid scale-up. The partnership with Tempus AI further strengthens Median's commercial strategy, leveraging established networks in oncology and precision medicine.
What we're watching
- Execution Risk
- How Median will manage the phased U.S. launch strategy and scale up operations to meet the expected operational sites in Q3 2026.
- Market Adoption
- Whether the clinical and economic value proposition of eyonis® LCS will drive broad adoption among U.S. lung cancer screening programs.
- Strategic Partnerships
- The pace at which Median can secure additional non-exclusive distribution agreements with top-tier imaging and cloud technology partners.
Related topics